课题基金 / 基金详情

University of Texas M.D. Anderson Cancer SPORE-Leukemia

University of Texas M.D. Anderson Cancer SPORE-Leukemia
德克萨斯大学安德森医学博士癌症孢子-白血病
批准号:
6604606
负责人:
HAGOP KANTARJIAN
金额:
$250.0万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-05 至 2008-04-30

项目摘要

项目成果

HAGOP KANTARJIAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The University of Texas M.D. Anderson Cancer Center is proposing a Specialized Program of Research Excellence (SPORE) in Leukemia. The primary goal of this Leukemia SPORE is to cultivate and facilitate innovative and significant translational research in the biologic, genetic and clinical aspects of leukemia to improve understanding, therapy, and prognosis. The multidisciplinary group of investigators in the Leukemia SPORE will accomplish this goal through effective integration of laboratory, epidemiologic and clinical investigations. Such activity will further our understanding of genetic susceptibility and leukemogenic molecular processes in leukemia, leading to novel, molecularly targeted strategies in leukemia. The SPORE is designed with 6 research projects and 3 core resources, as well as programs for developmental research and career development. The research projects are designed to target specific areas important in leukemia. Project 1 - Epigenetics of Drug Resistance in Acute Leukemia -targets methylation for therapy in leukemia Project 2 -Adoptive Cellular Therapy of Myeloid Leukemia - targets the use of MPO-Specific Cytotoxic T Lymphocytes (CTL) to treat leukemia Project 3 - Concerted Blockade of Oncoprotein Activity - targets sequential DNA, RNA and oncoprotein blockage in leukemia Project 4 -PPAR-gamma Nuclear Transcription Factor: A Novel Target for Leukemia Therapy - targets PPAR-gamma expression for leukemia therapy Project 5 - Molecular Epidemiology of AML Risk and Progression - evaluates genetic-molecular susceptibilities to development of AML through studies of relevant detoxifying and carcinogenesis-promoting pathways Project 6 - Response of AML Patients to FLT3 Inhibitors - targets FLT3 ligand inhibition in leukemias expressing FLT3 mutations or internal tandem duplication (ITD) Core and other resources are: Core A - Administration, Core B - Pathology and Tissue, Core C - Biostatistics & Data Management, Developmental Research Program, and Career Development Program. Through this leukemia SPORE, our research team will make a significant impact on leukemia prognosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epigenetics and Epigenetic Therapy in AML
Career Development Program
Administrative Core
Career Development Program
海外基金